Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board.
Researchers identify key regulators involved in genesis of multiple sclerosis lesions
By means of CRISPR screening, LMU researchers have provided the first ever comprehensive molecular characterization of T cell infiltration into the central nervous system of
September 23, 2023